onclive.comOncLive
onclive.com Profile
onclive.com
Sub Domains:nursing.onclive.com giants.onclive.com
Title:OncLive
Description:OncLive serves as a connection to everything oncology, including interviews and videos from thought leaders and cutting edge articles and resources.
Discover onclive.com website stats, rating, details and status online.Use our online tools to find owner and admin contact info. Find out where is server located.Read and write reviews or vote to improve it ranking. Check alliedvsaxis duplicates with related css, domain relations, most used words, social networks references. Go to regular site
onclive.com Information
Website / Domain: |
onclive.com |
HomePage size: | 704.396 KB |
Page Load Time: | 0.858967 Seconds |
Website IP Address: |
54.167.141.86 |
Isp Server: |
Amazon Technologies Inc. |
onclive.com Ip Information
Ip Country: |
United States |
City Name: |
Ashburn |
Latitude: |
39.043720245361 |
Longitude: |
-77.487487792969 |
onclive.com Keywords accounting
onclive.com Httpheader
Content-Type: text/html; charset=utf-8 |
Transfer-Encoding: chunked |
Connection: keep-alive |
x-nextjs-page: /index |
date: Sat, 09 Jan 2021 22:49:33 GMT |
x-powered-by: Next.js |
cache-control: public, max-age=0, must-revalidate |
etag: W/"a72e5-SDYQUPIZOg2P3jSVaXzLCFJN0Y0" |
x-vercel-cache: MISS |
age: 0 |
server: Vercel |
x-vercel-id: iad1::sfo1::vxln9-1610232572409-d3889f440f69 |
strict-transport-security: max-age=63072000 |
Content-Encoding: gzip |
onclive.com Meta Info
content="width=device-width" name="viewport"/ |
charset="utf-8"/ |
content="OncLive serves as a connection to everything oncology, including interviews and videos from thought leaders and cutting edge articles and resources. " name="description"/ |
54.167.141.86 Domains
onclive.com Similar Website
Domain |
WebSite Title |
onclive.com | OncLive |
onclive.com Traffic Sources Chart
onclive.com Alexa Rank History Chart
onclive.com Html To Plain Text
Search Spotlight ASH 2020 News Global Oncology News Neoadjuvant HER2+ CAR-T Cell Therapy Learning Module Colorectal Cancer Interactive Tools Targeted Therapy in Blastic Plasmacytoid Dendritic Cell Neoplasm Utilizing Tumor Metabolism in Solid Malignancies Specialty Biosimilars Breast Cancer Gastrointestinal Cancer Genitourinary Cancers Gynecologic Oncology Head & Neck Cancers Hematologic Oncology Immuno-Oncology Lung Cancer Melanoma & Skin Cancer Multiple Myeloma News Media Insights Medical World News News Network TV Peer Exchange Podcasts Rapid Readouts The Talk Conferences Conference Coverage Conference Listing Events Giants of Cancer Care Events Scientific Interchange Workshop Series PER Events State of the Science Summit / IPC Webinars Publications Resources Community Interactive Tools Learning Modules Partners Pipeline Report Sponsored CME Subscribe eNewsletter Advertise About Editorial Board CureToday.com TargetedOnc.com CancerNetwork.com Contact Us Privacy Terms & Conditions Do Not Sell My Information © 2021 MJH Life Sciences and . All rights reserved. Search Spotlight ASH 2020 News Global Oncology News Neoadjuvant HER2+ CAR-T Cell Therapy Learning Module Colorectal Cancer Interactive Tools Targeted Therapy in Blastic Plasmacytoid Dendritic Cell Neoplasm Utilizing Tumor Metabolism in Solid Malignancies Specialty See All > Biosimilars Breast Cancer Gastrointestinal Cancer Genitourinary Cancers Gynecologic Oncology Head & Neck Cancers Hematologic Oncology Immuno-Oncology Lung Cancer Melanoma & Skin Cancer Multiple Myeloma Advertise About Editorial Board CureToday.com TargetedOnc.com CancerNetwork.com Contact Us Privacy Terms & Conditions Do Not Sell My Information 2 Clarke Drive Suite 100 Cranbury, NJ 08512 © 2021 MJH Life Sciences ™ and . All rights reserved. Latest Oncology News Practicing Outside the Pharma Box in Breast Cancer January 9th 2021 By Dawn Fallik Martine J. Piccart discusses her journey into the breast cancer treatment space. More Innovation Is on Tap for 2021: Five Experts Describe Key Trends January 8th 2021 By Staff The development of additional molecularly targeted therapies and the search for enhanced immunotherapy regimens are expected to permeate the oncology landscape across a broad range of malignancies as 2021 unfolds. Osimertinib/Bevacizumab Improves ORR, But Fails to Prolong PFS in EGFR T790M+ NSCLC January 8th 2021 By Kristi Rosa January 8, 2021 — The combination of osimertinib plus bevacizumab failed to result in a statistically significant improvement in progression-free survival versus osimertinib alone in patients with advanced lung adenocarcinoma that harbored an EGFR T790M mutation. Advances in Immunotherapy in Metastatic Non–Small Cell Lung Cancer January 8th 2021 Non-small cell lung cancer is the most common histologic subtype of the disease, accounting for approximately 85% of cases. The recognition of targetable gene alterations and immune response has resulted in rapid changes to the therapeutic spectrum for NSCLC in recent years. Brexucabtagene Autoleucel Provides New Option for Patients With R/R MCL January 8th 2021 By Rachel Narozniak, MA Brexucabtagene autoleucel induced durable response in patients with relapsed/refractory mantle cell lymphoma, according to findings from the phase 2 ZUMA-2 trial, leading to an FDA approval for use in this patient population on July 24, 2020. Latest Oncology Videos Dr. Crane on the Benefit of Maintenance PARP Inhibitors in Ovarian Cancer Dr. Crane on the Benefit of Maintenance PARP Inhibitors in Ovarian Cancer Advanced Endometrial Cancer Advanced Endometrial Cancer Dr. Hutson on Challenges With Targeted Therapy in Non-Clear Cell RCC Dr. Hutson on Challenges With Targeted Therapy in Non-Clear Cell RCC Treatment Approach in Advanced Melanoma Treatment Approach in Advanced Melanoma First-Line Extensive-Stage SCLC: Examining the New Role of Combination Chemotherapy and Immunotherapy First-Line Extensive-Stage SCLC: Examining the New Role of Combination Chemotherapy and Immunotherapy Dr. Brown on the Utility of Minimally Invasive Surgery in Ovarian Cancer Dr. Brown on the Utility of Minimally Invasive Surgery in Ovarian Cancer Dr. Campbell on the Impact of the COVID-19 Pandemic in RCC Dr. Campbell on the Impact of the COVID-19 Pandemic in RCC Dr. Lee on the Tolerability of Ibrutinib/Cirmtuzumab in MCL and CLL Dr. Lee on the Tolerability of Ibrutinib/Cirmtuzumab in MCL and CLL Dr. Kumar on Sequencing Selinexor-Based Combinations in Multiple Myeloma Dr. Kumar on Sequencing Selinexor-Based Combinations in Multiple Myeloma Dr. Chauhan on Future Directions With Lutathera in GEP-NETs Dr. Chauhan on Future Directions With Lutathera in GEP-NETs Dr. Mai on Guidelines for Genetic Testing in CRC Dr. Mai on Guidelines for Genetic Testing in CRC Hussain and Taplin Talk Gender-Specific Struggles, Career Lessons in GU Oncology Hussain and Taplin Talk Gender-Specific Struggles, Career Lessons in GU Oncology Dr. Braunstein on Management Strategies in Multiple Myeloma Dr. Braunstein on Management Strategies in Multiple Myeloma Dr. Grigg on the Results of the CheckMate-214 Trial in RCC Dr. Grigg on the Results of the CheckMate-214 Trial in RCC Dr. Lin on the Emergence of CAR T-Cell Therapy in Multiple Myeloma Dr. Lin on the Emergence of CAR T-Cell Therapy in Multiple Myeloma Dr. Sznol on Toxicities Associated With Immunotherapy in Melanoma Dr. Sznol on Toxicities Associated With Immunotherapy in Melanoma Dr. Chiorean on the Role of Genetic Testing in Pancreatic Cancer Dr. Chiorean on the Role of Genetic Testing in Pancreatic Cancer Dr. Janjigian on the Expanding Treatment Armamentarium in HER2+ Gastric Cancer Dr. Janjigian on the Expanding Treatment Armamentarium in HER2+ Gastric Cancer Dr. Patel on a Subgroup Analysis of the NAPOLI-1 Trial in Pancreatic Cancer Dr. Patel on a Subgroup Analysis of the NAPOLI-1 Trial in Pancreatic Cancer Dr. Sweet on the Awareness and Mitigation of AEs Associated With Ponatinib in CLL Dr. Sweet on the Awareness and Mitigation of AEs Associated With Ponatinib in CLL Dr. Ailawadhi on the Potential Role of Melflufen in Multiple Myeloma Dr. Ailawadhi on the Potential Role of Melflufen in Multiple Myeloma Dr. McGregor on the Focus of Future Research Efforts in RCC Dr. McGregor on the Focus of Future Research Efforts in RCC Dr. O'Shaughnessy on the Rationale for the MonarchE Trial in Breast Cancer Dr. O'Shaughnessy on the Rationale for the MonarchE Trial in Breast Cancer All Oncology News FDA Updates Label for Darolutamide in Nonmetastatic CRPC to Include OS Data January 8th 2021 By Kristi Rosa January 8, 2020 - The FDA has approved a supplemental new drug application to add overall survival and other secondary end point data from the phase 3 ARAMIS trial to the prescribing information for darolutamide for the treatment of patients with nonmetastatic prostate cancer. NICE Rejects Nivolumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma January 8th 2021 By Kristi Rosa January 8th, 2021 - The United Kingdom’s National Institute for Health and Care Excellence has issued guidelines recommending against nivolumab for use in patients with recurrent or metastatic head and neck squamous cell carcinoma who experienced disease progression during or after platinum-based chemotherapy. FDA Grants Fast Track Designation to Zenocutuzumab for Metastatic NRG1+ Solid Tumors January 8th 2021 By Kristi Rosa January 8, 2021 — The FDA has granted a fast track designation to zenocutuzumab for the treatment of patients with metastatic solid tumors that harbor NRG1 gene fusions and have progressed on standard-of-care treatment. Need for Molecular Testing in Lung Cancer Is Underscored as Additional Targets Emerge January 8th 2021 By Erica DiNapoli Yujie Zhao, MD, PhD, highlights molecular testing and how it's a critical component of the treatment selection process in lung cancer, as a host of effective drugs have since been developed to target al...
onclive.com Whois
"domain_name": "ONCLIVE.COM",
"registrar": "GoDaddy.com, LLC",
"whois_server": "whois.godaddy.com",
"referral_url": null,
"updated_date": [
"2020-08-03 18:28:07",
"2020-08-03 18:28:05"
],
"creation_date": "2009-08-05 13:27:46",
"expiration_date": "2023-08-05 13:27:46",
"name_servers": [
"NS-1350.AWSDNS-40.ORG",
"NS-140.AWSDNS-17.COM",
"NS-1699.AWSDNS-20.CO.UK",
"NS-796.AWSDNS-35.NET"
],
"status": [
"clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited",
"clientRenewProhibited https://icann.org/epp#clientRenewProhibited",
"clientTransferProhibited https://icann.org/epp#clientTransferProhibited",
"clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited",
"clientTransferProhibited http://www.icann.org/epp#clientTransferProhibited",
"clientUpdateProhibited http://www.icann.org/epp#clientUpdateProhibited",
"clientRenewProhibited http://www.icann.org/epp#clientRenewProhibited",
"clientDeleteProhibited http://www.icann.org/epp#clientDeleteProhibited"
],
"emails": "abuse@godaddy.com",
"dnssec": "unsigned",
"name": null,
"org": null,
"address": null,
"city": null,
"state": "New Jersey",
"zipcode": null,
"country": "US"